课题基金 / 基金详情

项目摘要

项目成果

Andrea Marzi的其他基金

相似基金

相关文献

中文摘要
翻译
实验室开发了单独表达SARS-CoV-2刺突蛋白或与埃博拉病毒糖蛋白(EBOV GP)联合表达的2种候选疫苗。对仓鼠的研究表明,在SARS-CoV-2攻击后,单剂量鼻内或肌肉注射(IM)疫苗可保护动物免受疾病的侵害。当我们在SARS-CoV-2攻击前10天给恒河猴接种单剂量VSV-SARS2-EBOV疫苗时,只有通过IM途径接种的动物没有出现COVID-19的迹象,而接种IN疫苗的动物则出现了肺部病变(Furuyama等人,未发表的数据)。
英文摘要
The lab developed 2 vaccine candidates expressing the SARS-CoV-2 spike protein alone or in combination with the Ebola virus glycoprotein (EBOV GP). Hamster studies revealed that a single dose of either vaccine administered intranasally or intramuscularly (IM) protected the animals from disease after SARS-CoV-2 challenge. When we vaccinated rhesus macaques 10 days prior to SARS-CoV-2 challenge with a single dose of the VSV-SARS2-EBOV vaccine, only animals vaccinated by the IM route showed no signs of COVID-19, whereas the IN vaccinated animals did including lung lesions (Furuyama et al., unpublished data). Together with Dr. Munsters Virus Ecology Section, we studied the receptor usage of beta-coronaviruses using a VSV-based pseudoparticle system. We found that SARS-CoV-2 uses ACE2 as an entry receptor into cells (Letko et al., Nature Microbiology 2020). Furthermore, we collaborated with Dr. Munster on the establishment of a mouse model for SARS-CoV-2 in order to be able to test antivirals and vaccines (Yinda et al., 2020; PMID 32803199). In order to expand our understanding of human cytokine responses during COVID-19, we are analyzing human serum samples collected over time from patients from Indiana. In addition, we are determining IgG responses to SARS-CoV-2 in these samples and are looking into the potential of antibody-dependent enhancement of infection in these samples (Shifflett, Furuyama et al., unpublished data). Lastly, TLR4 and TLR7/8 agonists have shown to be beneficial as a treatment against influenza virus infections. In addition, TLR7/8 have been demonstrated to play a role in SARS-CoV-1 infection and pathogenesis. Therefore, we are testing both agonists as a potential treatment against SARS-CoV-2 infections in rodents. This project is in very early stages.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immunobiology, molecular virology and countermeasures of highly pathogenic viruses
Immunobiology, molecular virology and countermeasures of highly pathogenic viruses
Countermeasures against COVID-19
Immunobiology, molecular virology and countermeasures of highly pathogenic viruses
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    乔安娜
  • 依托单位: